SMPD1 and myeloid sarcoma: The genetic inhibition of aSMase/ceramide prevents the classical MS-like pathophysiology in the experimental autoimmune encephalomyelitis (EAE) model, including BBB disruption, leukocyte extravasation, and demyelination [58].